TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH Awards to Advance First-in-Class Engineered IgA Monoclonal ...
TigaTx will use the ARPA-H and NIH funding to progress its lead program, TIGA-001, an IgA anti-EGFR neutrophil engager, into the clinic and generate clinical proof-of-concept data for its engineered IgA platform TigaTx will also apply the ARPA-H funding to …